You are here:

linagliptin + metformin (Jentadueto)

Advice

following an abbreviated submission

linagliptin plus metformin combination tablets (Jentadueto®) is accepted for restricted use within NHS Scotland.

Indication under review: for the treatment of adult patients with type 2 diabetes mellitus in combination with insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control when insulin and metformin alone do not provide adequate glycaemic control.

SMC restriction: to use in patients for whom a combination of linagliptin and metformin is an appropriate choice of therapy and the fixed doses are considered appropriate.

For patients in whom combination therapy with linagliptin and metformin is appropriate, it has the potential to reduce the pill burden at no additional cost.
 

Drug Details

Drug Name: linagliptin + metformin (Jentadueto)
SMC Drug ID: 1057/15
Manufacturer: Boehringer Ingelheim Ltd
Indication: for the treatment of adult patients with type 2 diabetes mellitus in combination with insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control when insulin and metformin alone do not provide adequate glycaemic control.
BNF Category:
Sub Category: 6.1 Drugs used in diabetes
Submission Type: Abbreviated Submission
Status: Restricted
Date Advice Published: 8 June 2015

Back